Skip to main content
. 2024 Jul 11;14:16030. doi: 10.1038/s41598-024-67126-2

Figure 1.

Figure 1

Biological changes during CDK4/6 inhibition in vitro. (A) T47D and MCF7 cells were treated with increasing doses of palbociclib or ribociclib +/− fulvestrant (1 nM) for 72 h. Shown are representative graphs of cell viability redouts determined by Hoechst 33342. Data was normalised to untreated cells and three independent experiments were performed. Mean values ± SEM are shown. (B) T47D and MCF7 cells were treated with palbociclib or ribociclib (100 or 500 nM) for 24, 72 or 144 h and expression of p-RB1 and Lamin-B1 was assessed by western blot. Actin was used as a loading control. (C) T47D and MCF7 cells were treated with palbociclib or ribociclib (100 or 500 nM) for 24, 72 or 144 h and SA-β-gal activity was determined by flow cytometry. Data was normalised to untreated cells and three independent experiments were performed. Mean values ± SEM are shown.